1 hr ago
Janssen-Cilag International NV Release: Results From Head-To-Head...
Poster presented Tuesday 16th September 14:15 - 15:15 Note: This press release corresponds to EASD abstracts #826 and #817 Janssen-Cilag International NV today announced analyses based on head-to-head studies of INVOKANAA versus JANUVIA as dual and triple therapy options with metformin and metformin plus sulfonylureas, respectively, amongst patients with type 2 diabetes. These data highlight the importance of weight change for weight-related quality of life and physical health satisfaction and support the cost effectiveness of canagliflozin.1 These results were presented at the 50th European Association for the Study of Diabetes in Vienna, Austria .
Mon Sep 15, 2014
The Journal of Investigative Dermatology
Inhibition of Melanogenesis by the Antidiabetic Metformin
E-mail: email@example.com Received 6 January 2014; Revised 28 March 2014; Accepted 4 April 2014 Accepted article preview online 22 April 2014; Advance online publication 5 June 2014 Several reports have demonstrated the inhibitory effect of metformin, a widely used drug in the treatment of type 2 diabetes, on the proliferation of many cancers including melanoma. Recently, it has been shown that metformin is able to modulate the cAMP level in the liver.
Sat Sep 13, 2014
Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared...
Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden. This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus who fail to reach glycated hemoglobin a 7% were collected from the Swedish National Diabetes Register.
Intellipharmaceutics International Inc. (I) - Pharmaceuticals &...
The company holds expertise in research, development and manufacture of novel and generic targeted-release and controlled-release oral solid dosage drugs. Its product portfolio includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR and Generic Pristiq.
Thu Sep 11, 2014
Lexicon Announces A Publication In The American Diabetes Association's Journal, Diabetes Care
Results from Phase 2b Clinical Study in Patients with Type 2 Diabetes Provide Evidence that SGLT1 inhibition with LX4211 Provides a Clinically Meaningful Benefit Lexicon Pharmaceuticals, Inc. , announced a publication in the online edition of the American Diabetes Association's journal, Diabetes Care, entitled, "Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, in Type 2 Diabetes on Metformin Monotherapy". The publication provided detailed results from the Phase 2b clinical study of LX4211 that Lexicon conducted in patients with type 2 diabetes.
Wed Sep 10, 2014
Children with autism participate in medication-related weight-gain study
Vanderbilt University is one of four sites in the United States and Canada to enroll children with autism in a study to examine weight gain commonly experienced while taking antipsychotic medication. Medications prescribed in up to 20 percent of children with autism, including Risperdal, Abilify, Seroquel and Zyprexa, often cause substantial weight gain and put children at greater risk for developing diabetes.
Prediabetes may increase the risk of Cancer
Chinese scientists looked at 16 studies on the link between cancer and prediabetes when blood sugar levels are elevated, but aren't high enough to qualify as diabetes. Prediabetics had a 15-percent increased overall risk of cancer but the association was strongest for stomach, colorectal, liver, pancreatic, breast and endometrial cancers.
Biologists Delay The Aging Process By 'Remote Control' Of A Gene
Biologists have found that increasing the amount of the gene AMPK that can slow the aging process throughout the entire body when activated remotely in key organ systems. AMPK that is a key energy sensor in cells; it gets activated when cellular energy levels are low.
AstraZeneca UK Limited - Pharmaceuticals & Healthcare - Deals and...
The company develops and markets medicines. Its products include exenatide prolonged-release suspension for injection, rosuvastatin, dapagliflozin, saxagliptin, atenolol, lidocaine, lisinopril dihydrate, ceftaroline fosamil, goserelin acetate, zolmitriptan, metformin hydrochloride, felodipine, propranolol hydrochloride and dapagliflozin.
Tue Sep 09, 2014
Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce...
Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50 th EASD Annual Meeting 28 abstracts presented, including data on empagliflozin, an SGLT2 inhibitor recently approved in the European Union and in the US as Jardiance A )--Data to be presented at the European Association for the Study of Diabetes Annual Meeting in Vienna, Austria, will add to the extensive clinical evidence supporting the efficacy and safety profile of the diabetes portfolio from the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance. In addition, physician insights will be presented from IntroDiaa , the largest global survey of its kind in Type 2 Diabetes .
DGAP-News: Poxel Raises EUR10 Million from New Investors to Progress...
News: Poxel S.A. / Key word : Financing Poxel Raises EUR10 Million from New Investors to Progress Clinical Development of Two Novel Type 2 Diabetes Therapies 09.09.2014 / 09:00 --------------------------------------------------------------------- Poxel Raises EUR10 Million from New Investors to Progress Clinical Development of Two Novel Type 2 Diabetes Therapies Lyon, France, September 9, 2014 - Poxel SA announces today, that it has raised EUR10 million through a Series B extension with the Large Venture investment division of Bpifrance and a debt facility from Kreos Capital. The Series B financing, originally led by Edmond de Rothschild Investment Partners now totals EUR18 million .
Fri Sep 05, 2014
Merck KGaA Breaks Ground on Facility in China
Merck KGaA's biopharmaceuticals division held the groundbreaking ceremony for its new pharmaceutical manufacturing facility in Nantong, China, on Aug. 27, 2014. The new facility, which will be the group's second largest pharmaceutical manufacturing facility worldwide, will focus on the bulk production and packaging of Glucophage, Concor, and Euthyrox, the company's brands for the treatment of diabetes, cardiovascular diseases, and thyroid disorders, respectively.
Thu Sep 04, 2014
Grapefruit and helichrysum extract combat diabetes and obesity
In the Nutrition Department at the University of Navarra in Spain, Professor Alfredo Martinez and lecturer Fermin Milagro made a clinical breakthrough. They found out that both grapefruit and helichrysum extract can effectively combat diabetes and obesity.
Mon Sep 01, 2014
The Conestoga Herb Guild to hold Herb Fest
Most people assume all diabetics are on insulin or some oral medication like Metformin.
Thu Aug 28, 2014
Incretin, insulinotropic and glucose-lowering effects of whey protein ...
Since protein ingestion is known to stimulate the secretion of glucagon-like peptide-1 , we hypothesised that enhancing GLP-1 secretion to harness its insulinotropic/beta cell-stimulating activity with whey protein pre-load may have beneficial glucose-lowering effects in type 2 diabetes.
Fri Aug 22, 2014
Diabetes Self Management
New Approach for Neuropathy Pain?
Pain from diabetic neuropathy can be debilitating for people who have the condition, and it can be difficult to treat, with only an estimated 40% to 60% of those affected achieving partial relief .
Wed Aug 20, 2014
Boston Therapeutics, Inc. Completes Enrollment Of Patients With Type ...
Boston Therapeutics, Inc. , a developer of complex carbohydrate therapeutics to treat diabetes, has completed enrollment of its Phase IIb clinical study on BTI-320 in the United States.
NuSirt Biopharma Launches First Clinical Trial
NuSirt Biopharma , Inc., is initiating a clinical trial with a goal of demonstrating whether the company's patented technology may enhance the ability of a common Type 2 diabetes medication, metformin, to control blood sugar.
Tue Aug 19, 2014
Diabetes Self Management
Metformin Study Currently Recruiting
If you have Type 2 diabetes , you may be interested in a multisite study that is currently recruiting participants to evaluate the effectiveness of an extended-release version of the oral diabetes drug metformin versus the immediate-release version of the medicine.